Oesophageal adenocarcinoma

Overview

Oesophageal adenocarcinoma (OAC) is a malignant tumour arising from the glandular (adenoid) cells lining the lower portion of the oesophagus. It is distinct from squamous cell carcinoma (SCC), which originates from the flat squamous cells lining the upper and middle oesophagus and is strongly linked to smoking and alcohol consumption.

Over the past four decades, the incidence of OAC has risen dramatically in Western countries, making it the predominant histological subtype of oesophageal cancer in the UK, USA, Australia, and Western Europe. This rise parallels the increasing prevalence of obesity and gastro-oesophageal reflux disease (GORD).

Key Facts at a Glance

Aetiology and Risk Factors: The Pathway to Cancer

Understanding OAC requires understanding the Metaplasia-Dysplasia-Carcinoma Sequence. The normal oesophagus is lined by stratified squamous epithelium, designed to withstand mechanical abrasion. It is not resistant to chemical injury from gastric acid and bile.

1. Chronic Gastro-Oesophageal Reflux Disease (GORD)

Persistent reflux of acidic gastric contents and duodenal bile salts causes chronic inflammation (reflux oesophagitis). This is the primary driver.

2. Barrett’s Oesophagus (Intestinal Metaplasia)

In response to chronic injury, the squamous epithelium is replaced by columnar epithelium resembling the intestine (complete with goblet cells). This process is called intestinal metaplasia.

• Diagnosis: Requires both endoscopic suspicion (salmon-pink mucosa extending ≥1cm above the GOJ) and histological confirmation of intestinal metaplasia (goblet cells).
• Length Matters:
• Short-segment Barrett’s (SSBE): < 3 cm circumferential length. Lower absolute cancer risk.
• Long-segment Barrett’s (LSBE): ≥ 3 cm. Higher risk due to larger surface area for mutation accumulation.

3. Dysplasia (Intraepithelial Neoplasia)

Genetic instability leads to architectural and cytological abnormalities confined within the basement membrane.

• Low-Grade Dysplasia (LGD): Mild architectural distortion, nuclear stratification limited to basal half. Risk: ~0.5–1% per patient-year.
• High-Grade Dysplasia (HGD): Severe architectural complexity (cribriforming, budding), marked nuclear atypia, loss of polarity, mitotic figures at surface. Risk: ~6–10% per patient-year progression to invasive cancer.
• Note: “Indefinite for Dysplasia” (IND) is a category used when inflammation or technical artefacts obscure assessment; requires optimisation of acid suppression and repeat endoscopy.

4. Invasive Adenocarcinoma

Breach of the basement membrane into the lamina propria (T1a), submucosa (T1b), muscularis propria (T2), or beyond.

Summary of Risk Factors

How Does It Look: Endoscopic and Histopathological Appearance

This section details the visual and microscopic characteristics essential for diagnosis and staging.

1. Endoscopic Appearance (White Light & Advanced Imaging)

The endoscopic appearance evolves along the metaplasia-dysplasia-carcinoma sequence. High-definition white light endoscopy (HD-WLE) is the baseline; Virtual Chromoendoscopy (NBI, BLI, i-Scan) and Chromoendoscopy (Acetic Acid, Indigo Carmine) are standard for detection and delineation.

A. Barrett’s Oesophagus (Non-Dysplastic / Indefinite / Low-Grade Dysplasia)

• Prague C&M Classification: Standardised reporting of circumferential extent (C) and maximum extent (M) of columnar mucosa above the GOJ (e.g., C3M5).
• Visual Features:
• Salmon-pink / Velvety mucosa: Contrasts with pale, glossy squamous epithelium (Z-line irregularity).
• Tongues / Islands: Proximal extensions of columnar mucosa.
• Vascular Pattern (NBI/BLI): Regular mucosal pattern. Fine, uniform capillary network (mesh-like) within glands. No abnormal vessels.
• Surface Pattern (NBI/BLI): Regular villous/ridge pattern (Type I/II).

B. High-Grade Dysplasia (HGD) & Early Adenocarcinoma (T1a – Mucosal)

Endoscopists look for the “Four Signs” of Neoplasia (Paris Classification morphology + Vascular/Surface patterns).

C. Advanced Adenocarcinoma (T1b Sm+ / T2-T4)

• Ulcerated Mass (Type 2): Large, fungating, necrotic tumour with raised, indurated edges. Central ulcer crater with slough.
• Infiltrative / Stricture (Type 3/4): Concentric narrowing (“napkin ring”), rigid oesophagus, inability to pass endoscope. Mucosa may look relatively normal proximally (submucosal spread).
• Fistulisation: Communication with trachea/bronchus (tracheo-oesophageal fistula) or aorta (aorto-oesophageal fistula – catastrophic haemorrhage).

2. Histopathological Appearance (Microscopy)

Diagnosis is confirmed by biopsy (forceps bite) or resection specimen (EMR/ESD/Surgical).

A. Barrett’s Metaplasia (Intestinal Type)

• Architecture: Tubular glands, regular spacing, perpendicular to muscularis mucosae.
• Cells: Goblet cells (hallmark) – distinct cytoplasmic vacuole filled with blue acidic mucin (Alcian Blue pH 2.5 positive, PAS negative). Columnar absorptive cells (brush border), Paneth cells (basal eosinophilic granules), Stem cells (base).
• No Dysplasia: Nuclei basal, uniform, minimal mitotic activity confined to lower third.

B. Dysplasia (Intraepithelial Neoplasia) – Vienna Classification

• Low-Grade Dysplasia (LGD):
• Nuclear stratification extending to middle/upper third of cytoplasm.
• Nuclear hyperchromasia, mild pleomorphism.
• Mitoses may be seen above basal zone but not at surface.
• Architecture largely preserved (tubular).
• High-Grade Dysplasia (HGD) / Carcinoma In Situ:
• Architectural complexity: Cribriforming (back-to-back glands, no stroma), budding, branching, papillary infolding.
• Cytological atypia: Marked pleomorphism, loss of polarity (nuclei haphazard), prominent nucleoli, high N:C ratio.
• Mitotic figures: Frequent, abnormal forms, extending to surface epithelium.
• Apoptosis: Increased apoptotic bodies.
• Crucial Distinction: Basement membrane INTACT. No invasion into lamina propria.

C. Invasive Adenocarcinoma

• T1a (Mucosal / Intramucosal): Invasion through basement membrane into lamina propria but not through muscularis mucosae.
• Risk of Lymph Node Metastasis (LNM): Low (< 2-3%) if well/moderately differentiated, no lymphovascular invasion (LVI), depth < 500µm (sm1 equivalent not applicable here, but depth matters).
• T1b (Submucosal): Invasion through muscularis mucosae into submucosa.
• Sm1 (Superficial): < 500 µm from muscularis mucosae.
• Sm2 (Deep): ≥ 500 µm.
• LNM Risk: Sm1 ~ 8-15%; Sm2 ~ 20-30%+. LVI is the strongest predictor.
• Histological Grade (Differentiation):
• G1 (Well): >95% gland formation.
• G2 (Moderate): 50–95% glands.
• G3 (Poor): <50% glands / solid sheets / signet ring cells.
• Special Variants:
• Signet Ring Cell Carcinoma: >50% signet ring cells (mucin pushes nucleus to periphery). Poor prognosis, difficult endoscopic detection (linitis plastica).
• Adenosquamous Carcinoma: Mixed glandular and squamous differentiation.
• HEPACAM2 / Claudin-18.2: Emerging immunohistochemical targets for therapy.

D. Immunohistochemistry (IHC) Panel (Used for Diagnostic Clarification)

Symptoms: Clinical Presentation

OAC is insidious. Early stages (Tis, T1a) are almost always asymptomatic or cause only mild, non-specific reflux symptoms. Symptoms typically manifest once the tumour circumference narrows the lumen significantly (>50-60% stenosis) or invades adjacent structures.

1. Primary Oesophageal Symptoms (Local Effects)

Dysphagia (Difficulty Swallowing) – The Cardinal Symptom

• Prevalence: > 90% at diagnosis.
• Progression: Classic “Solid → Semi-solid → Liquid” sequence.
• Stage 1: Meat, bread, raw vegetables (“sticking” sensation retrosternally).
• Stage 2: Soft foods, mashed potato.
• Stage 3: Liquids, saliva (complete obstruction risk).
• Mechanism: Mechanical obstruction + loss of oesophageal distensibility (desmoplastic reaction).
• Associated Behaviour: “Washing down” food with water; avoiding social meals; regurgitation of undigested food hours after eating.

Odynophagia (Painful Swallowing)

• Sharp, burning, or squeezing retrosternal pain triggered by swallowing.
• Indicates ulceration, mucosal breach, or invasion into the muscularis propria/mediastinum.
• Differentiate from heartburn (burning rising from epigastrium, unrelated to swallowing act).

Regurgitation & Aspiration

• Effortless return of undigested food/fluid (no nausea/retching).
• Nocturnal cough, recurrent pneumonia, hoarseness: Suggests aspiration due to oesophageal stasis or tracheo-oesophageal fistula (TOF).
• TOF presents with coughing immediately upon swallowing liquids.

Reflux Symptoms (Pyrosis / Heartburn / Acid Brash)

• Paradoxically, long-standing severe reflux may improve as the tumour causes a functional stricture (preventing reflux) or the mucosa becomes metaplastic/less sensitive.
• New-onset reflux > age 55 or refractory reflux (failing high-dose PPI) mandates endoscopy.

2. Constitutional / Systemic Symptoms

• Unintentional Weight Loss: > 10% body weight in 3–6 months. Driven by reduced intake (dysphagia), cancer cachexia (cytokine-driven catabolism), and malabsorption.
• Anorexia / Early Satiety: Tumour bulk, gastric involvement (Siewert II/III), or metastatic peritoneal disease.
• Fatigue / Anaemia: Chronic occult blood loss (iron deficiency anaemia) or anaemia of chronic disease. Iron deficiency anaemia in a male or post-menopausal female = GI malignancy until proven otherwise.

3. Symptoms of Local Invasion (Locally Advanced Disease – T3/T4)

4. Symptoms of Metastatic Disease (Stage IV / M1)

• Liver (M1b – most common): RUQ pain, hepatomegaly, jaundice (late), ascites, abnormal LFTs (alk phos, GGT).
• Lungs / Pleura (M1a): Dyspnoea, pleural effusion, cough, haemoptysis.
• Peritoneum / Omentum (M1b): Ascites, abdominal distension, Sister Mary Joseph nodule (umbilical metastasis), ovarian masses (Krukenberg tumour).
• Distant Lymph Nodes (M1a – e.g., Supraclavicular/Virchow’s node / Left Supraclavicular = Troisier’s sign): Palpable hard, fixed nodes.
• Bone: Pain, pathological fracture, hypercalcaemia.
• Brain: Headaches, seizures, focal neurology (rare compared to lung cancer).

5. Paraneoplastic Syndromes (Rare but Important)

• Acquired Acanthosis Nigricans: Velvety hyperpigmentation axillae/neck (insulin/IGF-1 receptor cross-reactivity).
• Dermatomyositis / Polymyositis: Proximal muscle weakness, heliotrope rash, Gottron’s papules.
• Hypertrophic Osteoarthropathy (HOA): Digital clubbing, periostitis (bone pain), joint effusions.
• Trousseaus Syndrome (Migratory Thrombophlebitis): Hypercoagulability, recurrent DVT/PE.

“Alarm Symptoms” Requiring Urgent Endoscopy (NICE NG12 / ESGE Guidelines)

Clinicians and patients should have a low threshold for referral if ANY of the following are present, especially in combination:

1. Dysphagia (Progressive, solids first).
2. Odynophagia.
3. Unintentional Weight Loss (>5% in 3-6 months).
4. Iron Deficiency Anaemia (Unexplained, Men/Post-menopausal women).
5. New-onset Dyspepsia/Reflux age > 55 years (or > 45 with risk factors).
6. Refractory Reflux (Symptoms persist despite 8 weeks high-dose PPI).
7. Persistent Vomiting (Unexplained).
8. Upper GI Bleed (Haematemesis/Melaena) with risk factors.
9. Known Barrett’s Oesophagus with change in symptom pattern.

Diagnosis and Staging Workup

A structured, multidisciplinary approach is mandatory.

1. Diagnostic Endoscopy (Index Endoscopy)

• High-Definition White Light (HD-WLE) + Virtual Chromoendoscopy (NBI/BLI/i-Scan).
• Systematic Biopsy Protocol:
• Visible Lesion: Targeted biopsies (4-quadrant, centre, edges).
• Barrett’s Segment: Seattle Protocol – 4-quadrant biopsies every 1-2 cm + targeted biopsies of any visible abnormality.
• Dilation: If stricture prevents passage, gentle dilation (bougie/balloon) before staging EUS/CT is often needed to allow tumour visualisation and stenting if required.
• Endoscopic Tattooing: India ink or endoscopic clips placed proximal/distal to tumour for surgical/radiotherapy localisation.

2. Endoscopic Ultrasound (EUS) – Gold Standard for T & N Staging (Local)

• Radial Echoendoscope: 360° view. Assesses T-stage (layer penetration) and N-stage (node size, shape, echogenicity).
• Fine Needle Aspiration (FNA/FNB): Performed on suspicious nodes (round, hypoechoic, sharp borders, > 8-10mm, central necrosis) or coeliac axis nodes.
• Accuracy: T-stage ~80-90%; N-stage ~70-80% (imaging only); N-stage >90% with FNA.
• Limitation: Cannot pass tight strictures (requires prior dilation); overstages T-stage if fibrosis/inflammation mimics invasion.

3. Cross-Sectional Imaging: CT Thorax/Abdomen/Pelvis (Portal Venous Phase + Arterial if Liver Mets suspected)

• Purpose: M-Staging (Distant mets), Assessment of T4 invasion (trachea, aorta, spine, lung), N-staging (extra-oesophageal nodes: coeliac, supraclavicular, lung), Fitness assessment (liver volume, lung parenchyma).
• PET-CT (FDG): Recommended for all potentially curable patients (Stage I-III).
• Detects occult distant mets (upstages 10-15%).
• Assesses metabolic response to neoadjuvant therapy.
• False positives: Inflammation (oesophagitis, pneumonia post-obstructive).
• False negatives: Small volume peritoneal deposits, mucinous/signet ring tumours (low FDG avidity).

4. Staging Laparoscopy (Diagnostic Laparoscopy)

• Indication: Mandatory for Siewert Type II/III (GOJ) tumours and Type I > T2 / Node+ prior to curative resection.
• Yield: Detects occult peritoneal metastases (10-20% missed by PET-CT), positive cytology (malignant ascites).
• Procedure: Peritoneal lavage for cytology + visual inspection + biopsy suspicious deposits.

5. Biomarker Testing (Mandatory for Stage IV / Metastatic)

• HER2 (IHC + FISH): Target for Trastuzumab / Fam-trastuzumab deruxtecan.
• PD-L1 (CPS – Combined Positive Score): Target for Pembrolizumab / Nivolumab.
• MSI / dMMR (IHC or PCR): Target for Pembrolizumab (1st line agnostic).
• Claudin 18.2 (CLDN18.2): Emerging target (Zolbetuximab – approved in some regions for gastric/GEJ).
• NGS Panel: Tumour Mutational Burden (TMB), FGFR2, MET, KRAS, PIK3CA (Clinical trial eligibility).

TNM Staging (AJCC 8th Edition / UICC 8th Edition) – Specific for Oesophageal Adenocarcinoma

Note: Staging differs for SCC. Siewert Type I (distal oesophagus) and Type II (true cardia) use Oesophageal staging. Siewert Type III (subcardial) uses Gastric staging.

T Category (Primary Tumour)

N Category (Regional Lymph Nodes)

Regional nodes include: Periesophageal, gastric cardia/lesser curvature, coeliac, paratracheal, tracheobronchial, subcarinal, paraesophageal hiatus.

• N0: No regional metastasis.
• N1: Metastasis in 1–2 regional nodes.
• N2: Metastasis in 3–6 regional nodes.
• N3: Metastasis in ≥ 7 regional nodes.

M Category (Distant Metastasis)

• M0: No distant metastasis.
• M1: Distant metastasis (Liver, Lung, Peritoneum, Non-regional nodes e.g. supraclavicular, Bone, Brain).

Stage Grouping (Prognostic Stage Groups)

Management: A Stage-Based Multidisciplinary Approach

All patients MUST be discussed at a Specialist Upper GI Multidisciplinary Team (MDT) meeting (Surgeon, Oncologist, Radiologist, Pathologist, Nurse Specialist, Dietitian, Palliative Care).

1. Endoscopic Therapy (Curative Intent for Tis / T1a / Selected T1b Sm1)

Goal: Organ preservation, avoid oesophagectomy morbidity/mortality.

2. Neoadjuvant Therapy + Surgery (Standard for Resectable T2-T4a, N+)

The CROSS Trial regimen is the global benchmark.

The CROSS Regimen (Neoadjuvant Chemoradiotherapy – nCRT)

• Radiotherapy: 41.4 Gy in 23 fractions (1.8 Gy/fx, 5 days/week).
• Chemotherapy (Concurrent):
• Carboplatin AUC 2 mg/mL/min (Day 1, 8, 15, 22, 29).
• Paclitaxel 50 mg/m² (Day 1, 8, 15, 22, 29).
• Surgery Timing: 4–6 weeks post-RT completion (allows downstaging, fibrosis maturation, haematological recovery).
• Pathological Complete Response (pCR / ypT0N0): Achieved in ~25-30% (Adenocarcinoma slightly lower than SCC). Strongest prognostic factor.

Alternative: Neoadjuvant Chemotherapy (Perioperative) – FLOT / MAGIC / OE05

• FLOT (5-FU, Leucovorin, Oxaliplatin, Docetaxel): 4 cycles pre-op, 4 cycles post-op. Standard for Gastric/GEJ (Siewert III) / FLOT4-AIO trial. Increasingly used for distal OAC/GEJ (Siewert II) as alternative to CROSS (EPOC trial / Neo-AEGIS trial comparing FLOT vs CROSS).
• MAGIC / OE05 (ECF/ECX/EOX): 3 cycles pre, 3 cycles post. Older standard, inferior to FLOT/CROSS.

Surgical Resection: Oesophagectomy

• Approaches:
• Ivor Lewis (Transthoracic – Right Thoracotomy + Laparotomy): Most common for distal OAC. Lower anastomotic leak rate (intrathoracic), good lymphadenectomy (2-field).
• McKeown (Three-field – Right Thoracotomy + Laparotomy + Cervical Incision): For proximal/mid tumours. Higher recurrent laryngeal nerve injury (RLNI) & leak rate (cervical anastomosis), but better proximal margin clearance.
• Transhiatal (Orringer – Laparotomy + Cervical, No Thoracotomy): For early tumours / frail patients / high thoracic aorta risk. Limited mediastinal lymphadenectomy. Higher anastomotic leak (cervical).
• Minimally Invasive (MIE – Thoracoscopic/Laparoscopic/Robotic): Standard of care in high-volume centres. Reduced pulmonary complications, less blood loss, faster recovery, equivalent oncological outcomes (TIME, ROMIO, MIRO trials). Robotic (RAMIE) offers wristed articulation for anastomosis/lymphadenectomy.
• Lymphadenectomy: 2-Field (Mediastinal + Abdominal) standard for OAC. 3-Field adds cervical (recurrent laryngeal nodes) – debated for OAC, standard for upper/mid SCC.
• Reconstruction: Gastric Tube (Conduit) pulled up via Posterior Mediastinum (preferred – shortest route, vascularised by Right Gastroepiploic artery). Substernal/Retrosternal (higher leak risk, compression) or Anterior (rare).
• Key Quality Metrics: R0 resection rate > 90%, ≥ 15-20 nodes examined, Anastomotic Leak Rate < 10-15%, 90-day Mortality < 3-5% (High Volume Centres).

3. Definitive Chemoradiation (dCRT) – Non-Surgical Curative Intent

• Indications: T4b (Unresectable), Medically Inoperable (Frailty, Severe COPD/Heart failure), Patient Refusal, Cervical Oesophagus (to avoid laryngectomy).
• Dose: 50.4 Gy / 28 fractions (Standard) or 50 Gy / 25 fractions (Hypofractionated). Concurrent Chemo: Cisplatin/5-FU (classic) or Carboplatin/Paclitaxel (CROSS dose) or FOLFOX.
• Salvage Surgery: High morbidity/mortality (20-40% complications), reserved for local recurrence only (no distant mets) in fit patients. Endoscopic surveillance strict (3-6 monthly).

4. Palliative & Metastatic Management (Stage IV)

Goal: Symptom control, quality of life, survival prolongation.

Systemic Therapy (1st Line – Standard of Care)

Local Palliation of Dysphagia

1. Self-Expanding Metal Stents (SEMS): First line for rapid relief. Covered (prevent tumour ingrowth, migration risk higher) vs Uncovered (embed, tumour ingrowth). Antireflux valve stents if GOJ involved.
2. Endoscopic Dilation (Bougie/Balloon): Bridge to stent/chemo; risk of perforation (high post-RT). Used for benign strictures post-treatment.
3. Radiotherapy (Palliative): 30 Gy/10 fx or 20 Gy/5 fx. Good for bleeding, pain, dysphagia recurrence post-stent. Delayed effect (2-3 wks).
4. Brachytherapy (Intraluminal): High dose rate (HDR). Longer dysphagia-free survival vs stent alone, but slower onset.
5. Laser / APC / Resection: Debulking for obstruction (palliative EMR/ESD).

Nutritional Support

• Jejunostomy (Surgical/Radiological): Feeding access during nCRT/Surgery/Recovery. Standard at time of oesophagectomy.
• PEG / RIG: If stomach not used for conduit or gastric outlet obstruction.
• Parenteral Nutrition (PN): Only if enteral access impossible/failed.
• ERAS (Enhanced Recovery After Surgery): Early oral intake (Day 1-2), early mobilisation, multimodal analgesia (Thoracic Epidural / Paravertebral / Erector Spinae Plane Block).

Follow-Up and Survivorship

Surveillance Schedule (Post-Curative Intent Treatment)

No high-level evidence supports survival benefit from intensive imaging, but standard practice aims for early detection of recurrence (salvageable) or metachronous cancers.

Long-Term Sequelae & Quality of Life (QoL) Management

Survivors face unique challenges requiring proactive management.

Prevention and Screening

Primary Prevention

1. Weight Management: Target BMI < 25 kg/m²; reduce visceral adiposity.
2. Smoking Cessation: Risk reduces over time (~50% reduction after 10-15 years cessation).
3. Diet: High intake of fresh fruits, vegetables, whole grains, dietary fibre. Limit processed/red meat.
4. Alcohol Moderation: Within low-risk guidelines.
5. PPI Use: Only for symptom control. No evidence PPIs prevent cancer progression in non-dysplastic Barrett’s. Long-term PPI risks (CKD, fractures, infections, B12 def, dementia – debated) must be weighed.

Secondary Prevention: Surveillance of Barrett’s Oesophagus

• Target Population: Confirmed Intestinal Metaplasia (Biopsy proven).
• Intervals (BSG / ACG / ESGE Guidelines):
• Non-Dysplastic (NDBE):
• Segment < 3cm (SSBE): Every 3-5 years (BSG: 3-5yr; ACG: 3-5yr).
• Segment ≥ 3cm (LSBE): Every 2-3 years.
• Indefinite for Dysplasia (IND): Optimise PPI 8-12 weeks → Repeat Endoscopy 6-12 months.
• Low-Grade Dysplasia (LGD): Confirmed by 2 expert GI pathologists.
• Option A (Preferred): Endoscopic Eradication Therapy (RFA ± EMR). High cure rate, prevents progression.
• Option B: Surveillance 6-12 Monthly (If patient declines/ unfit). High progression risk.
• High-Grade Dysplasia (HGD): Endoscopic Eradication Therapy (ESD/EMR + RFA) is Standard of Care. Surveillance only if unfit for any intervention.

Chemoprevention (Not Standard Routine Care)

• Aspirin / NSAIDs: Observational data suggests ~30-40% risk reduction in Barrett’s patients. AspECT Trial (Aspirin + High dose PPI) showed trend but not definitive significance for cancer prevention alone; cardiovascular benefit drives use. Not recommended solely for cancer prevention due to bleeding risk.
• Statins: Observational association with reduced risk; no RCT evidence.

Prognosis and Outcomes

Prognosis is heavily stage-dependent. Population-based data (SEER, NCRAS) include many elderly/frail patients not receiving curative treatment; clinical trial/MDT-selected data is better.

5-Year Overall Survival (OS) Estimates (Contemporary Series / SEER 2010-2016)

Prognostic Factors (Multivariate)

1. Pathological Stage (ypTNM): Strongest.
2. Resection Margin Status (R0 vs R1): R1 (microscopic +ve) = worse OS, higher local recurrence.
3. Lymphovascular Invasion (LVI) / Perineural Invasion (PNI): Independent adverse factors.
4. Treatment Response: TRG (Tumour Regression Grade) 1/2 (Mandard/Becker/RCPath) vs 3/4/5.
5. Lymph Node Yield & Ratio: Positive Node Ratio (pN+ / Total examined) > 0.2-0.3 adverse.
6. Comorbidity / Frailty (ACE-27 / CCI / CFS): Determines treatment tolerance.
7. Nutritional Status: Sarcopenia (CT psoas index), Pre-op weight loss >10% = poor surgical outcomes.

Patient-Centred Care: Practical Advice for Living with OAC

Nutrition: “Food is Medicine”

• “Little and Often”: 6-8 small meals/snacks daily.
• Texture Modification: Soft, moist, minced, puréed (IDDSI Framework Levels 4-6).
• Fortification: Double cream, cheese, oils, nut butters, protein powders added to meals.
• Hydration: Sip fluids between meals (200ml limit with meals) to avoid early satiety/dumping.
• Supplements: Prescribed Oral Nutritional Supplements (ONS) – High Protein, High Calorie (e.g., Fortisip Compact, Ensure Plus, Fresubin). Aim > 1.5g protein/kg/day.
• Vitamin B12: Lifelong IM Hydroxocobalamin 1mg every 3 months post-oesophagectomy (loss of parietal cells/intrinsic factor + bacterial overgrowth).

Managing Common Symptoms

• Reflux at Night: Bed head elevation (blocks under bed legs, not just pillows). Last meal 3-4 hrs before bed. Alginate raft former (sodium alginate) at bedtime.
• Diarrhoea / Bile Acid Malabsorption (BAM): Common post-oesophagectomy (loss of reservoir, rapid transit). Trial Cholestyramine / Colesevelam / Colestipol (take 1hr away from other meds). Low fat diet trial.
• Dumping Syndrome: Acarbose 50-100mg with meals (late dumping). Octreotide SC (specialist only).
• Stricture / Food Bolus Obstruction: Do not force vomiting. Sip warm water / fizzy drink. Seek urgent endoscopy if > 1-2 hours / unable saliva / distress.

Psychosocial Support

• Specialist Nurse (CNS/Key Worker): Central point of contact.
• Dietitian: Mandatory at diagnosis, pre-op, post-op, annually.
• Physiotherapy: Pre-habilitation (incentive spirometry, exercise), Post-op chest clearance, mobility.
• Psychology / Counselling: Fear of recurrence, swallowing anxiety, body image.
• Patient Organisations: Oesophageal Patients Association (OPA – UK), Oesophageal Cancer Fund (Ireland), ECAN (US), Cancer Council (Aus). Peer support invaluable.

Emerging Research and Future Directions

1. Neoadjuvant Immunotherapy (ICI) + Chemo ± RT: CheckMate 577 (Adjuvant Nivolumab post nCRT+Surgery for residual disease) – New Standard Adjuvant for ypN+ or ypT≥1. KEYNOTE-585 / MATTERHORN / CheckMate 648/649 (Perioperative ICI+Chemo ± RT) – Practice changing data imminent/presented (Path CR rates increasing).
2. Organ Preservation Strategies: “Watch and Wait” after Complete Clinical Response (cCR) to dCRT/nCRT. Rigorous surveillance (Endoscopy + EUS + Biopsy + PET-CT q3-6m). Avoids surgery morbidity. Selected patients (SCC > OAC currently, but OAC trials ongoing – e.g. ESOPEC, GERD).
3. Liquid Biopsy (ctDNA / ctRNA): MRD (Minimal Residual Disease) detection post-surgery (Signatera, Guardant Reveal, RaDaR). Guides adjuvant therapy decisions (CheckMate 577 used ctDNA exploratory). Early detection of recurrence months before imaging.
4. Targeted Therapies: Claudin 18.2 (Zolbetuximab), FGFR2b (Bemarituzumab), HER2 ADCs (T-DXd, RC48), KRAS G12C inhibitors.
5. AI in Endoscopy: Computer-Aided Detection (CADe) and Diagnosis (CADx) for Barrett’s dysplasia and early cancer (real-time NBI analysis). Improves detection rates for non-experts.
6. Microbiome Modulation: Role of oesophageal/gastric microbiome in carcinogenesis and treatment response.

Glossary of Key Terms

References

Clinical Guidelines

• National Institute for Health and Care Excellence (2018) Oesophago-gastric cancer: assessment and management in adults. NICE Guideline [NG83]. London: NICE. Available at: https://www.nice.org.uk/guidance/ng83 (Accessed: [Current Date]).
• European Society for Medical Oncology (ESMO) / European Society of Gastroenterology (ESGE) / European Society for Radiotherapy and Oncology (ESTRO) (2023) ‘Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’. Annals of Oncology, 34(4), pp. 333–356. DOI: 10.1016/j.annonc.2022.12.008.
• British Society of Gastroenterology (2019) ‘British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus’. Gut, 68(9), pp. 1587–1605. DOI: 10.1136/gutjnl-2019-318484.
• American Joint Committee on Cancer (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer. (Ch. 16: Esophagus and Esophagogastric Junction).
• National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2.2024. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org (Accessed: [Current Date]).

Landmark Clinical Trials

• Shapiro, J. et al. (2015) ‘Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial’. The Lancet Oncology, 16(9), pp. 1090–1098. DOI: 10.1016/S1470-2045(15)00040-6.
• van Hagen, P. et al. (2012) ‘Preoperative chemoradiotherapy for esophageal or junctional cancer’. New England Journal of Medicine, 366(22), pp. 2074–2084. DOI: 10.1056/NEJMoa1112088.
• Al-Batran, S.E. et al. (2019) ‘Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial’. The Lancet, 393(10184), pp. 1948–1957. DOI: 10.1016/S0140-6736(18)32557-1.
• Kelly, R.J. et al. (2021) ‘Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)’. New England Journal of Medicine, 384(13), pp. 1191–1203. DOI: 10.1056/NEJMoa2032125.
• Sun, J.M. et al. (2021) ‘Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study’. The Lancet, 398(10302), pp. 759–771. DOI: 10.1016/S0140-6736(21)01201-6.
• Janjigian, Y.Y. et al. (2021) ‘First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial’. The Lancet, 398(10294), pp. 27–40. DOI: 10.1016/S0140-6736(21)00797-2.
• Shitara, K. et al. (2020) ‘Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer (DESTINY-Gastric01): a randomised, open-label, phase 2 trial’. The Lancet Oncology, 21(11), pp. 1449–1459. DOI: 10.1016/S1470-2045(20)30477-1.

Key Textbooks & Reviews

• Fitzgerald, R.C. et al. (2024) ‘Oesophageal adenocarcinoma’. The Lancet, 403(10427), pp. 683–698. DOI: 10.1016/S0140-6736(23)02555-7.
• Lagergren, J. et al. (2017) ‘Oesophageal cancer’. The Lancet, 390(10110), pp. 2383–2396. DOI: 10.1016/S0140-6736(17)31462-9.
• Spechler, S.J. and Souza, R.F. (2014) ‘Barrett’s esophagus’. New England Journal of Medicine, 371(9), pp. 836–845. DOI: 10.1056/NEJMra1314730.
• Lordick, F. et al. (2022) ‘Oesophageal cancer: ESMO Clinical Practice Guidelines’. Annals of Oncology, 33(10), pp. 992–1004. (Note: Superseded by 2023 update above).
• Cancer Research UK (2024) Oesophageal cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer (Accessed: [Current Date]).

Patient Support Organisations

• Oesophageal Patients Association (OPA) UK. Available at: https://www.opa.org.uk/
• Oesophageal Cancer Fund (Ireland). Available at: https://www.ocf.ie/
• Esophageal Cancer Action Network (ECAN) USA. Available at: https://ecan.org/
• Cancer Council Australia. Available at: https://www.cancer.org.au/cancer-information/types-of-cancer/oesophageal-cancer
• Macmillan Cancer Support. Available at: https://www.macmillan.org.uk/cancer-information-and-support/oesophageal-cancer